Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease.

[1]  V. Wong,et al.  Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis , 2017, Hepatology.

[2]  D. Brenner,et al.  Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood , 2016, Hepatology.

[3]  F. Servant,et al.  Changes in blood microbiota profiles associated with liver fibrosis in obese patients: A pilot analysis , 2016, Hepatology.

[4]  Rohit Loomba,et al.  MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice. , 2016, Journal of hepatology.

[5]  N. Schork,et al.  Shared genetic effects between hepatic steatosis and fibrosis: A prospective twin study , 2016, Hepatology.

[6]  J. Chiang,et al.  Cholesterol 7α-hydroxylase protects the liver from inflammation and fibrosis by maintaining cholesterol homeostasis[S] , 2016, Journal of Lipid Research.

[7]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[8]  J. Bajaj,et al.  Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects? , 2016, Gastroenterology.

[9]  Xin Liu,et al.  Inhibition of the translocation and extracellular release of high-mobility group box 1 alleviates liver damage in fibrotic mice in response to D-galactosamine/lipopolysaccharide challenge , 2016, Molecular medicine reports.

[10]  Lawrence A. David,et al.  The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota , 2016, Hepatology.

[11]  R. Loomba,et al.  Targeting Dysbiosis for the Treatment of Liver Disease , 2016, Seminars in Liver Disease.

[12]  J. Borén,et al.  Confounding Effects of Metformin on the Human Gut Microbiome in Type 2 Diabetes. , 2016, Cell metabolism.

[13]  Hong-wei Zhang,et al.  Associations of gut-flora-dependent metabolite trimethylamine-N-oxide, betaine and choline with non-alcoholic fatty liver disease in adults , 2016, Scientific Reports.

[14]  Jun Wang,et al.  Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota , 2015, Nature.

[15]  N. Schork,et al.  Heritability of Hepatic Fibrosis and Steatosis Based on a Prospective Twin Study. , 2015, Gastroenterology.

[16]  J. Venter,et al.  Library preparation methodology can influence genomic and functional predictions in human microbiome research , 2015, Proceedings of the National Academy of Sciences.

[17]  Manuel L Gonzalez-Garay,et al.  Plasma metabolomic profiles enhance precision medicine for volunteers of normal health , 2015, Proceedings of the National Academy of Sciences.

[18]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[19]  Mary E Rinella,et al.  Nonalcoholic fatty liver disease: a systematic review. , 2015, JAMA.

[20]  S. Subramaniam,et al.  Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: a prospective study , 2015, Gut.

[21]  Mats Fredrikson,et al.  Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up , 2015, Hepatology.

[22]  Zhen Wang,et al.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[23]  Beiwen Zheng,et al.  Alterations of the human gut microbiome in liver cirrhosis , 2014, Nature.

[24]  Andmorgan R. Fisher,et al.  Altered profile of human gut microbiome is associated with cirrhosis and its complications. , 2014, Journal of hepatology.

[25]  G. Svegliati-Baroni,et al.  Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice , 2014, Hepatology.

[26]  R. Schwabe,et al.  CCL20 mediates lipopolysaccharide induced liver injury and is a potential driver of inflammation and fibrosis in alcoholic hepatitis , 2014, Gut.

[27]  Jens Roat Kultima,et al.  Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota , 2015, Nature.

[28]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[29]  H. Nittono,et al.  Modulation of the fecal bile acid profile by gut microbiota in cirrhosis. , 2013, Journal of Hepatology.

[30]  Lixin Zhu,et al.  Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH , 2013, Hepatology.

[31]  Richard A. Flavell,et al.  Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity , 2012, Nature.

[32]  Giorgio Saracco,et al.  The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative study , 2011, Hepatology.

[33]  A. Baranova,et al.  Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.

[34]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[35]  B. Haas,et al.  A Catalog of Reference Genomes from the Human Microbiome , 2010, Science.

[36]  W. R. Wikoff,et al.  Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites , 2009, Proceedings of the National Academy of Sciences.

[37]  B. Roe,et al.  A core gut microbiome in obese and lean twins , 2008, Nature.

[38]  Yosuke Osawa,et al.  TLR4 enhances TGF-β signaling and hepatic fibrosis , 2007, Nature Medicine.

[39]  Andy Liaw,et al.  Classification and Regression by randomForest , 2007 .

[40]  T. Takagi,et al.  MetaGene: prokaryotic gene finding from environmental genome shotgun sequences , 2006, Nucleic acids research.

[41]  M. Pop,et al.  Metagenomic Analysis of the Human Distal Gut Microbiome , 2006, Science.

[42]  S. Sanderson,et al.  The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.

[43]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[44]  Leo Breiman,et al.  Random Forests , 2001, Machine Learning.

[45]  Peter D. Karp,et al.  The Pathway Tools software , 2002, ISMB.

[46]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[47]  C. W. Moss,et al.  Production of hydrocinnamic acid by clostridia. , 1970, Applied microbiology.